⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9724332 | 0.99 | — | — | |
| SCHEMBL19210808 | 0.99 | — | — | |
| SCHEMBL15969015 | 0.80 | PSEN1 (0.31) | — | |
| SCHEMBL342325 | 0.80 | PSEN1 (0.31) | — | |
| Bicarbonate SCHEMBL9303198 | 0.76 | — | — | |
| SCHEMBL21628076 | 0.75 | — | — | |
| SCHEMBL505619 | 0.74 | — | — | |
| SCHEMBL2511023 | 0.74 | — | — | |
| SCHEMBL322605 | 0.74 | — | — | |
| SCHEMBL28933685 | 0.73 | ALDH1A1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240082413-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-03-14 | — | — | US | disclosed |
| US-11633493-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-04-25 | — | — | US | disclosed |
| US-10973924-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-04-13 | — | — | US | disclosed |
| EP-2283373-B1 | ACCURATE QUANTIFICATION OF MAGNETIC SUSCEPTIBILITY IN MOLECULAR MRI | UNIV CORNELL (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200282073-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-09-10 | — | — | US | disclosed |
| US-10729782-B2 | Antibody-drug conjugate produced by binding through linker having hydrophilic structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-3632471-A1 | ANTIBODY-DRUG CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2020-04-08 | — | — | EP | disclosed |
| EP-2910573-B1 | ANTIBODY-DRUG CONJUGATE PRODUCED BY BINDING THROUGH LINKER HAVING HYDROPHILIC STRUCTURE | DAIICHI SANKYO CO LTD (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-10195288-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-02-05 | — | — | US | disclosed |
| US-20190008981-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-01-10 | — | — | US | disclosed |
| US-7052872-B1 | Bi-specific antibodies for pre-targeting diagnosis and therapy | IMMUNOMEDICS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060034759-A1 | Production and use of novel peptide-based agents with bispecific antibodies | IMMUNOMEDICS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| EP-1614690-A1 | PEPTIDE FRAGMENT OF LYVE-1 AND ANTIBODY AGAINST THE SAME | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005086612-A2 | FLUORINATED CARBOHYDRATE CONJUGATES | IMMUNOMEDICS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005077071-A2 | THERAPEUTIC AND DIAGNOSTIC CONJUGATES FOR USE WITH MULTISPECIFIC ANTIBODIES | IMMUNOMEDICS, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050136001-A1 | Fluorinated carbohydrate conjugates | IMMUNOMEDICS, INC. (US) | 2005-06-23 | — | — | US | disclosed |
| EP-1506018-A1 | DRUG PRE-TARGETING BY MEANS OF BI-SPECIFIC ANTIBODIES AND HAPTEN CONSTRUCTS COMPRISING A CARRIER PEPTIDE AND THE ACTIVE AGENT(S) | Immunomedics, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20050002945-A1 | Therapeutic and diagnostic conjugates for use with multispecific antibodies | IMMUNOMEDICS, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2003097105-A1 | DRUG PRE-TARGETING BY MEANS OF BI-SPECIFIC ANTIBODIES AND HAPTEN CONSTRUCTS COMPRISING A CARRIER PEPTIDE AND THE ACTIVE AGENT (S) | IMMUNOMEDICS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030198595-A1 | Use of bi-specific antibodies for pre-targeting diagnosis and therapy | IMMUNOMEDICS, INC. | 2003-10-23 | — | — | US | disclosed |